Seminars & Events
Thursday, September 11, 2014: Dr. Bevil Conway (Wellesley College) will speak on his research in visual neuroscience and color at 4:30 pm in Goodpaster Hall 195.
Monday, October 27, 2014: Dr. Todd Gould (University of Maryland Baltimore) will speak on "Genes to behaviors to treatments in bipolar disorder" at 4:45 pm in Goodpaster Hall 195.Friday, December 5, 2014: Dr. Brian Mathur (University of Maryland Baltimore) will speak on "Braking bad: Aberrant inhibitory neurotransmission in addiction" at 3:00 pm in Goodpaster Hall 195.
Blackwell, Robert (2008). Cognitive Deficits in Beta-Catenin Knockout Mice: An Endophenotype Approach to Modeling Bipolar Disorder
Mentor: Dr. Anne Marie Brady
Lithium is currently the only novel pharmacological treatment for bipolar disorder. Developing novel medications is inhibited by the lack of a valid animal model for bipolar disorder. At therapeutic concentrations, lithium inhibits GSK-3, disinhibiting beta-catenin. Beta-catenin overexpression decreases immobility in the forced swim test (correlated with depressive behavior) and amphetamine induced hyperlocomotion (correlated with manic behavior), suggesting beta-catenin is involved in the pathophysiology of bipolar disorder. A progressive beta-catenin knockout increased immobility time in the tail suspension test, but had no effect on immobility time in the forced swim test or hyperactivity, in male mice. The present study attempted to determine the validity of the progressive beta-catenin knockout model in female mice. Subjects had increased immobility time in the tail suspension test, but there was no effect of knockout on the forced swim test, baseline activity, or spatial working memory.